CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 299 enrolled
Drug / intervention
Emergen-C Core Super Orange Powder +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06654089
NCT06654089Phase 4Completed

A Real-World Evidence Study Evaluating Quality of Life Parameters Following Use of Emergen-C

HALEON·interventional·Posted Oct 23, 2024·Updated Apr 7, 2026

In Brief

A Phase 4 clinical trial evaluating Emergen-C Core Super Orange Powder and Placebo for Dietary Supplements. Completed, enrolled 299 participants across 1 site.

Detailed Summary

The purpose of this study is to determine how Emergen-C use can improve quality of life (QoL) in a real-world setting to help consumers and healthcare professionals understand the benefits of taking Emergen-C on a routine or daily basis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20252026
First PostedOct 23, 2024
Enrollment StartOct 30, 2024
Primary CompletionFeb 24, 2025
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 1.7 years ago

Interventions

Emergen-C Core Super Orange Powderdietary

A dietary supplement powder containing vitamin C, zinc, vitamin B6, vitamin B12, folate, and manganese.

Placebodietary

To ensure proper blinding, the placebo was formulated to be indistinguishable from Emergen-C in taste, appearance, and other sensory characteristics. The placebo therefore contained fructose, and the electrolytes potassium, magnesium, calcium, and sodium.